The COSMAM TRIAL a prospective cohort study of quality of life and cosmetic outcome in patients undergoing breast conserving surgery

Coriene J. L. M. Catsman¹*, Martinus A. Beek¹, Adri C. Voogd²,³, Paul G. H. Mulder¹ and Ernest J. T. Luiten¹

Abstract

Background: Cosmetic result in breast cancer surgery is gaining increased interest. Currently, some 30–40% of the patients treated with breast conserving surgery (BCS) are dissatisfied with their final cosmetic result. In order to prevent disturbing breast deformity oncoplastic surgical techniques have been introduced. The extent of different levels of oncoplastic surgery incorporated in breast conserving surgery and its value with regard to cosmetic outcome, patient satisfaction and quality of life remains to be defined. The aim of this prospective cohort study is to investigate quality of life and satisfaction with cosmetic result in patients with breast cancer, undergoing standard lumpectomy versus level I or II oncoplastic breast conserving surgery.

Methods: Female breast cancer patients scheduled for BCS, from 18 years of age, referred to our outpatient clinic from July 2015 are asked to participate in this study. General, oncologic and treatment information will be collected. Patient satisfaction will be scored preceding surgery, and at 1 month and 1 year follow up. Photographs of the breast will be used to score cosmetic result both by the patient, an independent expert panel and BCCT.Core software. Quality of life will be measured by using the BREAST-Q BCT, EORTC-QLQ and EQ-5D-5 L questionnaires.

Discussion: The purpose of this prospective study is to determine the clinical value of different levels of oncoplastic techniques in breast conserving surgery, with regard to quality of life and cosmetic result. Analysis will be carried out by objective measurements of the final cosmetic result in comparison with standard breast conserving surgery. The results of this study will be used to development of a clinical decision model to guide the use oncoplastic surgery in future BCS.

Trial registration: Central Commission of Human Research (CCMO), The Netherlands: NL54888.015.15. Medical Ethical Commission (METC), Maxima Medical Centre, Veldhoven, The Netherlands: 15.107. Dutch Trial Register: NTR5665, retrospectively registered, 02-25-2016.

Keywords: Breast conserving surgery, Oncoplastic surgery, Breast cancer, Quality of life, Cosmetic result, Patient reported outcomes

* Correspondence: cjlmcatsman@gmail.com; ccatsman@amphia.nl

¹Department of Surgery, Amphia Hospital, Molengracht 21, 4818, CK, Breda, The Netherlands

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Breast conserving surgery (BCS) is carried out since the late seventies of the former century. Studies with more than 20 years of follow up have shown its equivalency to mastectomy with regard to loco regional control and overall survival [1–4]. Currently, the majority of women with breast cancer (50–70%) is treated with BCS [5]. Apart from oncological adequate resection achievement of a good cosmetic result and high patient satisfaction are essential components of successful BCS. Psychological morbidity due to disfigurement following surgery for breast cancer therapy in patients were first reported in the early fifties [6]. However more thorough studies on QoL (psychosocial, physical and sexual well-being) originate only form the last 2 decades. This growing awareness for preservation of body image, cosmetic result and QoL is attenuated by the increasing prevalence of patients who survive breast cancer [7].

Today, some 30–40% of the patients report that they are disappointed with the final cosmetic result of BCS [8]. Breast asymmetry after BCS is significantly correlated with poor psychosocial functioning and fear of recurrence, which has negative impact on QoL [8, 9]. Poor cosmetic result is caused by contour defects, asymmetry of the breasts, malposition of the nipple, adhesions, and retractions due to large resection volumes, which can be attenuated by subsequent radiation therapy [10]. Tumor to breast ratio as well as localization of the tumour is accepted factors with regard to the risk to obtain an unsatisfactory cosmetic result. Several studies have reported that cosmetic failure rates are significantly higher when the tumour is located in the inner half of the breast, if lumpectomy volume exceeds >20% of the breast or more than 50–85 ml regardless of the size of the breast [11–14].

Both Audretsch and Gabka first introduced oncoplastic breast conserving surgery in the early nineties [15–17]. In order to prevent breast deformity many different oncoplastic techniques have been proposed to reshape and/or modify the appearance of the breast. Clough et al. described several of these oncoplastic surgical techniques in a quadrant-per-quadrant atlas [18]. Oncoplastic surgery (OPS) incorporated in BCS involves reconstruction of the resection defects by volume displacement techniques using adjacent breast tissue. With regard to volume displacement techniques 2 levels of OPS are recognized, based on the extent of the resection and the corresponding mammoplasty techniques [18]. Level I OPS includes local re-arrangement of volume defects of <10%, and level II OPS includes the volume displacement technique for volume defects of more than 10–30% volume.

Recognizing the risk of a potentially unfavourable cosmetic outcome is the first step in deciding when to incorporate OPS in BCS. Application of OPS is reported to expand the possibility of BCS thereby still achieving acceptable or good cosmetic results and QoL [19]. On the contrary, in a small subgroup of a recent Dutch retrospective study in 125 patients (74% BCS and 26% OPS) it was suggested that patients in whom conventional BCS was carried out scored significantly better than those treated with OPS when scored by BCCT.Core cosmetic result scoring software [20].

The exact role as well as the extent of OPS in BCS in order to ameliorate cosmetic outcome, patient satisfaction and quality of life remains rather ill defined. The former is partly due to lack of high quality studies on this issue.

In order to identify factors that affect cosmetic outcome and influence QoL a standardized method to evaluate cosmetic result is warranted. Currently, different methods are used to evaluate the cosmetic result of BCS, including panel evaluation using a photo scoring method, computer programs that objectively and automatically evaluate breast aesthetics by using patient photographs (BCCT.Core), the breast retraction assessment to measure breast asymmetry and patient opinion using QoL forms [21–24].

Patient satisfaction with cosmetic result, preservation of body image and QoL is mostly assessed by QoL questionnaires that mainly originate from plastic surgery reduction techniques that are not specifically validated for breast cancer patients undergoing BCS [25]. The BREAST-Q questionnaire is a validated survey instrument especially developed for patients undergoing breast surgery, measuring QoL (sexual, mental and physical wellbeing and satisfaction with breast). Recently the BREAST-Q BCT module was developed, which is specifically designed for patients undergoing BCS [26].

Proper evaluation of the possible additional value of OPS incorporated in standard BCS is limited due to lack of uniformity in measurements, validated quality of life questionnaires, objective scoring of cosmetic results and patient satisfaction. Current studies also lack a robust level of evidence partly due to study design, small numbers of patients, incomplete follow up and incomplete data on patient reported outcomes, including evaluations in which patients score photographs of their own breasts. In the first Dutch guideline of OPS an urgent need for studies comparing all objective and subjective scoring systems prospectively in well-designed study protocols is recommended [27].

Methods

The aim of this prospective cohort study is to assess the additional value of different levels of (oncoplastic) BCS in breast cancer patients with, with regard to quality of life and objective cosmetic outcome, in comparison with
conventional lumpectomy combined simple closure of the cavity. Secondly, this study will examine the value of different quality of life scoring systems in evaluating satisfaction with cosmetic results in patients undergoing BCS, with or without the use of oncoplastic techniques.

**Participants: Inclusion and exclusion criteria**

All female patients referred to our outpatient clinic from June 2015, eligible for BCS and BCS with OPS that are older than 18 years, will be evaluated for inclusion in this cohort study. Patients will be included in the study directly after signing informed consent and before the operation. Informed consent will be obtained and explained by a qualified nurse practitioner in the outpatient clinic. Patients who are not familiar with Dutch language or with a history of breast cancer and/or radiation therapy in the head/neck/axillary or breast region in the past will be excluded.

**Data collection**

For all patients in the study data will be collected prior to surgery (T0), 4 weeks after surgery (T1) and 1 year after surgery (T2) (Table 1: Data Collection). These data include:

- Oncologic diagnostics and treatment characteristics
- Patient questionnaires
- Photographs of the breast

**Patient characteristics**

Prior to surgery (T0) and 4 weeks after surgery (T1) patients will be asked to fill out a general questionnaire regarding marital status, ethnicity, breast size, body mass index (BMI), educational level and work. One year after surgery (T2) patients will be asked to complete a final general questionnaire including questions concerning the use of treatments for lymphedema, return to normal daily activities and work and their opinion of the final cosmetic result.

**Diagnostics and treatment characteristics**

Baseline characteristics including oncologic data will be collected of all patients containing information about histology, volume of the breast, hormone receptor status, tumour location and tumour size on magnetic resonance imaging (MRI), amount of removed breast tissue during lumpectomy, axillary surgery, re-excision, adjuvant radiotherapy and hormone therapy.

**Patient questionnaires**

Preoperatively (T = 0), patients will be asked to fill out the pre-operative breast-Q for BCT questionnaire (Additional file 1) measuring QoL, which contains questions related to psychosocial, physical and sexual wellbeing. Both at T = 1 and T = 2, patients will be asked to fill out the post-operative breast-Q for BCT questionnaire, which also contains questions about psychosocial, physical and sexual wellbeing. The breast-Q is a patient reported outcome instrument designed to standardize evaluation outcomes [26]. At T = 0, T = 1, T = 2 patients will also be asked to fill out the EQ-5D-5L (Additional file 2) and the EORTC-QLQ (Additional files 3 and 4) and the EQ-5D-5 L. EQ-5D-5 L is a health related QoL questionnaire (mobility, self-care, usual activities, pain/discomfort, anxiety and depression) in which patients rate their own health [28]. The EORTC-QLQ breast module is a questionnaire developed to assess the QoL of cancer patients [29].

**Photographs of the breast**

Standardized photographs of the breast of all patients will be made prior to surgery (T = 0), 4 weeks after surgery (T = 1) and 1 year after surgery (T = 2) by a professional medical photographer.

**Cosmetic result**

The value of different scoring systems to evaluate satisfaction with the cosmetic outcome in patients undergoing conventional lumpectomy and versus BCS and OPS will be examined [30]. Photographs of the breast will be assessed with quantitative and qualitative scoring systems. Qualitative scoring will be carried out by using a standardized score list for cosmetic result. Both an expert panel and patients will be asked to score the result. Since strong variation between observers is common when measuring cosmetic outcome, the expert panel will consist of at least five members, including both professionals and non-professionals, both male and female with different backgrounds [24]. The panel members will score all photographs individually at all three time points. The pre-operative cosmetic appearance of the breast (T = 0) will be used as a baseline and will be

| Table 1 Data collection | Pre-operative (T = 0) | 1 month post-operative (T = 1) | 1 year post-operative (T = 2) |
|-------------------------|----------------------|-------------------------------|-------------------------------|
| General questionnaire   | +                    | +                             | +                             |
| Breast-Q Pre-operative  | +                    |                               |                               |
| Breast-Q Post-operative | +                    | +                             | +                             |
| EORTC-QLQ and EQ-5D-5 L | +                    | +                             | +                             |
| Breast Photo            | +                    | +                             | +                             |
| Diagnostics & Treatment | –                    | –                             | –                             |
| Breast Photo            | +                    | +                             | +                             |
| Scoring Patient         |                      |                               |                               |
| Breast Photo Scoring    | –                    | –                             | –                             |
| BCCT.Core/Expert panel  |                      |                               |                               |

- = Professional + = Patient
scored by a qualitative scoring system by using the adjusted version of the patient self-assessment scoring system, developed by Vos et al. The original 11 items patient self-assessment scoring system of Vos et al., will be used to score cosmetic result at $T=1$ and $T=2$ [23].

Haloua et al. have suggested that patient self-evaluation of the cosmetic outcome should be incorporated in future studies apart from other evaluation methods. Self-evaluation reflects the psychological adaptation of the patient to the appearance of the breast [30]. All patients will be asked to score their own photographs at all three time points. Cosmetic appearance of the breast at $T=0$ and will be used as baseline. A patient version of the scoring list of Vos et al. to score the photographs will be used at $T=1$ and $T=2$. Evaluation of all scoring systems will be based on the percentage of the total score.

Quantitative scoring will be conducted by using BCCT.Core software that automatically evaluates breast aesthetics. BCCT.Core software is an objective method for the evaluation of cosmetic result in BCS [31]. BCCT. Core software was proven to provide valid cosmetic outcome scores compared to a panel evaluation and is used in several studies [30]. The investigator digitally marks the nipples, axillae and sternum, jugular notch; BCCT. Core software then identifies the relative difference between both breasts and nipples and the relative difference between nipples and inframammary fold difference. (Figure 1: example of BCCT.Core software).

**Objectives**
The aim of this single-centre prospective registration cohort study is to assess the additional value of different levels of oncoplastic BCS in patients with breast, with regard to quality of life and cosmetic outcome by objective measurements of the final cosmetic result in comparison with patients undergoing conventional lumpectomy. Secondly, study trial will examine the value of different quality of life scoring systems in evaluating satisfaction with cosmetic results in patients undergoing BCS.

**Treatment allocation**
All patients undergoing breast conserving surgery are requested to participate in this study irrespective of the pre-planned surgical technique to be performed. The decision with regard to the type of surgical technique is not strictly defined but depends on the preference of the individual surgeon taking into account tumour location, breast/tumour ratio, the quality of the breast tissue, breast size and degree of ptosis. In general, surgeons are recommended to perform oncoplastic surgery in case of expected resections of more than 10% of the breast volume as well as large lesions in the upper medial and lower medial and lower lateral quadrants. Planning is done by using shared decision-making. Including informing patients that more extensive procedures may need larger incisions. Surgical procedures are divided as follows:

1. Standard lumpectomy with/without minor volume replacement:
2. Level 1 oncoplastic surgery:
3. Level 2 oncoplastic surgery:

**Withdrawal and replacement**
Patients can leave the study at any time for any reason. The investigator can decide to withdraw a subject from the study for urgent medical reasons. Patients will not be replaced after withdrawal and will have regular
outpatient clinic check-up. These patients will be considered as “lost to follow-up”.

Sample size
Annually, approximately 450 new women are diagnosed with breast cancer in our surgical outpatient clinic (2011). Approximately 75% of these women are initially treated with BCS. Three operation types are considered: standard, level I and level II. The cosmetic score at 4 weeks is considered the primary outcome variable. From the presently available data the pre-operation level of the cosmetic score appeared to be comparable between the three operation types ($n = 151; p = 0.60$). The power calculation will be based on the upper limit of the 95% confidence interval of the pooled within operation type residual standard deviation of the cosmetic score at 4 weeks, adjusted for its pre-operation level. Based on estimates obtained from the present data this residual SD will be set at 16 points on a (0–100)-scale. Two comparisons between operation types will be made: level I with standard and level II with standard. According to Cohen’s $d$ a medium effect of 0.5 SD (= 8 points) will be considered to be minimally detectable. The test size alpha of either comparison with the standard operation will be set at a two-sided level of 0.027 according to Dunnett’s $t$, resulting in an overall alpha of 0.05 (two-sided). The resulting sample size per operation type is 75 (80% power) or 100 (90% power). Purpose is to recruit at least 75 patients per operation type, including the patients recruited so far.

Statistical analysis
Raw data summaries of patient, tumour and treatment characteristics will be made by operation type. Spearman’s correlation and Pearson’s correlation will be used in a descriptive way to assess the correlation of the mean score of total expert panel score, total patient score and automated calculations of the BCCT.Core software. Cosmetic result and quality of life will be measured at a descriptive way to assess the correlation of the mean score obtained from the present data this residual SD was 16 points on a (0–100)-scale. Two comparisons between operation types will be made: level I with standard and level II with standard. According to Cohen’s $d$ a medium effect of 0.5 SD (= 8 points) will be considered to be minimally detectable. The test size alpha of either comparison with the standard operation will be set at a two-sided level of 0.027 according to Dunnett’s $t$, resulting in an overall alpha of 0.05 (two-sided). The resulting sample size per operation type is 75 (80% power) or 100 (90% power). Purpose is to recruit at least 75 patients per operation type, including the patients recruited so far.

for operation type and the baseline level of both the cosmetic result and the quality of life instrument at hand, so as to assess the correlation between changes at $T = 1$ and $T = 2$ from what is known at $T = 0$. Effect of resection volume on the cosmetic score at $T = 1$ and $T = 2$ will be analysed using linear mixed modelling with adjustment for the potentially confounding effects of baseline cosmetic score, age, education, body mass index, tumour quadrant, operation type, possible re-operation and/or complications.

All statistical analysis will be performed with SPSS version 23.0 from IBM Software.

Adverse events
No adverse events as a result of this study are expected, as patients do not undergo any additional interventions. If any adverse events of one of these surgical methods are identified they will be reported to the medical ethical commission and hospital board.

Protocol changes
Important protocol modifications will be first submitted to a medical ethical commission and the hospital board. In case of approval all participants and the Dutch trial register will be informed.

Discussion
The COSMAM Trial is a first prospective cohort study that aims to define the role of different levels of additional OPS in BCS for breast cancer patient. This study compares objective and subjective scoring systems prospectively and is approved by a Dutch medical ethical board.

Since randomization for this type of surgery is virtually impossible the study observes the results of daily practice. This will give a real world experience of current breast saving treatment in an oncological breast cancer centre with multiple surgeons performing different levels of OPS in different patients according to their personal preference. We do realize that in the ideal setting patients with similar tumour types in the same quadrant of the breast should preferably be randomized between lumpectomy with oncoplastic surgery and conventional lumpectomy. However from both an ethical and practical point of view we feel that carrying out such a study could possibly affect cosmetic result and quality of life. Especially in patients with an expected removal of > 10% of the total breast volume as well as large lesions in the upper medial and lower medial and lower lateral quadrants. Based on the reports that application of OPS expands the possibility of BCS thereby still achieving acceptable or good cosmetic results and QoL [19]. Without OPS in these patients a mastectomy would be
considered because of high chance of deformation of the breast performing a standard lumpectomy.

All patients who are scheduled for BCS are asked to participate in this study. Our study population is considered to be representative a reflection of the Dutch community.

Despite literature describing the use of OPS there is no clear international standard describing the indications for application of different levels of OPS neither which technique is indicated in relation to the tumour site and the density of the breast tissue. Based on current literature OPS is recommended in patients with a tumour situated in the inner half of the breast, when lumpectomy exceeds >20% of total breast volume or more than 50–85 ml, regardless of the size of the breast [11–14, 27]. The techniques that are currently used and to what extent they are carried out mainly depends on the surgeon’s preference and expertise.

To implement OPS as a standard additional technique in BCS more data are needed regarding the clinical value of which patients benefit from OPS, thereby not only taking into account tumour characteristics and location but also type of breast tissue and opinion of the patient. The aim of the COSMAM trial is to assess the additional value of different levels of oncplastic BCS, with regard to QoL and cosmetic outcome by objective measurements of the final cosmetic result in comparison with patients undergoing conventional BCS. The patient and tumour characteristics correlated with a satisfying cosmetic result and QoL after OPS may give valuable information for development of decision-making tree when to use OPS and which technique will give the most satisfying and oncologic safe result.

The implementation of a decision-making tree for the indication of OPS follows the trend of adjusting breast cancer treatment to tumour type and location as well as specific patient characteristics. By personalizing BCS we will not only focus on the medical treatment of breast cancer patients but also on individual specific needs and personal preferences of the patient as a human being.

**Conclusion**

The purpose of this prospective study is to assess the clinical value of addition of different oncplastic techniques in breast conserving surgery, with regard to quality of life and cosmetic outcome by objective measurements of the final cosmetic result in comparison with standard breast conserving surgery. The results of this study can be used for development of a clinical decision model to guide the use of oncplastic breast techniques in order to establish personalized oncologic safe and cosmetic satisfying breast conserving treatment.

---

**Additional files**

**Additional file 1**: Sample Breast Q – BCT Module, Quality of Life Questionnaire. (PDF 335 kb)

**Additional file 2**: Sample EQ5D5L, Quality of Life Questionnaire. (PDF 106 kb)

**Additional file 3**: Sample EORTC QLQ C30, Quality of Life Questionnaire. (PDF 886 kb)

**Additional file 4**: Sample EORTC QLQ B23, Quality of Life Questionnaire. (PDF 225 kb)

**Abbreviations**

BCS: Breast Conserving Surgery; BMI: Body Mass Index (length²/weight); ER: Estrogen Receptor; Her2Neu: Human Epidermal Growth Factor Receptor 2; LR: Local recurrence; LRFs: Local recurrence free survival; MRI: Magnetic Resonance Imaging; OPS: Oncoplastic Breast Conserving Surgery; pBAD: Relative breast area difference; pBCE: Relative breast compliance evaluation; pBRA: Relative breast retraction assessment; PR: Progesterone receptor; pUNR: Relative upward nipple retraction; QoL: Quality of life; SN: Sentinel node procedure; SPSS: Statistical package for the social sciences

**Acknowledgements**

Special thanks to our nurse practitioners Mrs. J. Hover, J.A. Woolschot and D. van der Meer for all their hard work and effort. We also would like to thank the members of our expert panel: Dr. R. Tjong Joe Wai, Drs. W. Berrevoets, Miss J.A.M. Raïseng, Miss M.E. Neellemans and Mr. A. van Dongen for their voluntary participation in this study and The Amphia Hospital, Breda, The Netherlands, especially the department of Surgery for their facilitating services and support.

**Consent of publication**

Written consent was obtained from the patient to publish their image.

**Funding**

This study is partially funded by the Amphia Hospital Breda, the Netherlands.

**Authors’ contributions**

All authors read and approved the final manuscript. CC has made substantial contributions to conception and design of the study, acquisition of data, analysis and interpretation of data and drafted the manuscript. MB had substantial contribution to the conception and design of the study, material support and revised the manuscript critically. AV had substantial contribution to the design of the study is also responsible for the statistical analysis and revised the manuscript critically. PM had substantial contribution to the statistical analysis and revised the manuscript critically. EL had substantial contribution to the conception and design of the study, revising the manuscript critically for important intellectual content and has given final approval of the version to be published.

**Ethics approval and consent to participate**

The ethical requirements of this institution have been met; all patients signed informed consent before inclusion in this study. This study was approved by the Medical Ethical Commission (METC), Maxima Medical Centre, Veldhoven, The Netherlands (15.107) and is registered in the Dutch Trial Register: NTR5665 retrospectively registered, 02-25-2016. URL: http://www.trialregister.nl/trialreg/admin/rctsearch.asp?Term=cosmam

**Competing interests**

The authors declare that they have no competing interests.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

1. Department of Surgery, Amphia Hospital, Molengracht 21, 4818, CK, Breda, The Netherlands. 2. Department of Epidemiology, Maastricht University, PO Box 616, 6200, MD, Maastricht, The Netherlands. 3. Department of Research, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, The Netherlands.
References

1. Veronesi U, Sacconci R, Del Vecchio M, Banfi A, Clemente C, De Lena M, et al. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med. 1981;305(1):6–11.

2. Fisher B, Redmond C, Poisson R, Margolese R, Wolmark N, Wickerham L, et al. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med. 1989;320(1):822–8.

3. Fisher B, Bauer M, Margolese R, Poisson R, Pritch Y, Redmond C, et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med. 1985;312(11):665–73.

4. Veronesi U, Cascinelli N, Marianni L, Greco M, Sacconci R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347(16):1227–32.

5. Treatment of Early-Stage Breast Cancer. NIH Consens Statement Online; 1990. p. 1–19.

6. Bacon CL, Renneker R, Cutler M. A psychosomatic survey of cancer of the female breast following subcutaneous and modified radical mastectomy. Arch Gynecol Obstet. 1987;241(Suppl):S11–S16.

7. Baildam AD. Oncoplastic surgery for breast cancer. Br J Surg. 2008;95(1):40–9.

8. Losken A, Hamdi M. Partial breast reconstruction: current perspectives. Plast Reconstr Surg. 2009;124(3):722–36.

9. Waljee JF, Hu ES, Ubel PA, Smith DM, Newman LA, Alderman AK. Effect of cosmetic results following partial mastectomy and radiation therapy: a systematic review. Plast Reconstr Surg. 1999;104(2):409–20.

10. Audretsch W. Space-holding technic and immediate reconstruction of the breast by skin flap. Arch Gynecol Obstet. 1988;248(1):26–32.

11. Cochrane RA, Valasiadou P, Wilson AR, Al-Ghazal SK, Macmillan RD. Aesthetic results following partial mastectomy and radiation therapy. Plast Reconstr Surg. 1999;104(2):409–20.

12. Bulstrode NW, Shorrin S. Prediction of cosmetic outcome following conservative breast surgery using breast volume measurements. Breast. 2000;10(2):124–6.

13. Cochrane RA, Valasiadou P, Wilson AR, Al-Ghazal SK, Macmillan RD. Cosmesis and satisfaction after breast-conserving surgery correlates with the percentage of breast volume excised. Br J Surg. 2003;90(12):1505–9.

14. Al-Ghazal SK, Blamey RW, Stewart J, Morgan AA. The cosmetic outcome in early breast cancer treated with breast conservation. Eur J Surg Oncol. 1999;25(6):556–70.

15. Clough KB, Kroll SS, Audretsch W. An approach to the repair of partial mastectomy defects. Plast Reconstr Surg. 1999;104(2):409–20.

16. Audretsch W. Space-holding technic and immediate reconstruction of the female breast following subcutaneous and modified radical mastectomy. Arch Gynecol Obstet. 1987;241(Suppl):S11–9.

17. Gabka CJ, Bohmert H. Future prospects for reconstructive surgery in breast cancer. Semin Surg Oncol. 1996;12(1):67–75.

18. Clough KB, Ihrai T, Oden S, Kaufman G, Massey E, Nos C. Oncoplastic surgery for breast cancer based on tumour location and a quadrant-per-quadrant atlas. Br J Surg. 2012;99(10):1389–95.

19. Veiga DF, Veiga-Filho J, Ribeiro LM, Archangelo I Jr, Baldino PF, Caetano LV, et al. Quality-of-life and self-esteem outcomes after oncoplastic breast-conserving surgery. Plast Reconstr Surg. 2010;125(3):811–7.

20. Lansu JT, Essers M, Voogd AC, Luiten EJ, Buiks C, Groenendaal N, et al. The influence of simultaneous integrated boost, hypofractionation and oncoplastic surgery on cosmetic outcome and PROMs after breast conserving therapy. Eur J Surg Oncol. 2015;41(1):42–8.

21. Kim MK, Kim T, Moon HG, Jin US, Kim K, Kim J, et al. Effect of cosmetic outcome on quality of life after breast cancer surgery. Eur J Surg Oncol. 2015;41(3):346–52.

22. Immink JM, Putter H, Bartelink H, Cardoso JS, Cardoso MJ, van der Hulst-Vijgen MH, et al. Long-term cosmetic changes after breast-conserving treatment of patients with stage I-II breast cancer and included in the EORTC ‘boost versus no boost’ trial. Ann Oncol. 2012;23(10):2591–8.

23. Vos EL, Koning AH, Obdeijn IM, van Verschuer VM, Verhoef C, van der Spek PJ, et al. Preoperative prediction of cosmetic results in breast conserving surgery. J Surg Oncol. 2015;111(2):178–84.

24. Wiegle C, Collette L, Bartelink E, Borger JH, Breninkmeyer SJ, Horiot JC, et al. Validation of the methods of cosmetic assessment after breast-conserving therapy in the EORTC “boost versus no boost” trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups, European Organization for Research and Treatment of Cancer. Int J Radiat Oncol Biol Phys. 1999;45(3):667–76.

25. McIntosh J, ODonoghue JM. Therapeutic mammaplasty—a systematic review of the evidence. Eur J Surg Oncol. 2012;38(3):196–202.

26. Pusic AL, Kassen AF, Scott AM, Klok JA, Cordeiro PG, Cano SJ. Development of a new patient-reported outcome measure for breast surgery: the BREAST-Q. Plast Reconstr Surg. 2009;124(2):345–53.

27. Surgery DAoP. Guideline breast reconstruction. 2013.

28. Herdmann M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-SD (EQ-SD-5L). Qual Life Res. 2011;20(10):1727–36.

29. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.

30. Haloua MH, Krekel NM, Jacobs GJ, Zonderhuis B, Bouman MB, Buncamper ME, et al. Cosmetic outcome assessment following breast-conserving therapy: a comparison between BCCT.core software and panel evaluation. Int J Breast Cancer. 2014;2014:76860.

31. Cardoso MJ, Cardoso J, Amaral N, Azevedo I, Barreau L, Bernardo M, et al. Turning subjective into objective: the BCCT.core software for evaluation of cosmetic results in breast cancer conservative treatment. Breast. 2007;16(5):456–61.